UBS Starts Express Scripts (ESRX) at Neutral

October 6, 2016 7:07 AM EDT
Get Alerts ESRX Hot Sheet
Price: $69.69 -1.9%

Rating Summary:
    11 Buy, 16 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ESRX Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

UBS initiates coverage on Express Scripts (NASDAQ: ESRX) with a Neutral rating and a price target of $76.00.

Analyst Michael Cherny commented, "We are initiating coverage of Express Scripts with a Neutral rating and a $76 price target. ESRX is the last of the major standalone PBMs, pitching its model of alignment with customers as its key selling point. The company has stemmed the tide from multiple years of meaningful share losses (post-Medco acquisition) to return retention to normalized levels. Even through the losses, ESRX remained a cash flow generating machine, and the improved retention should stabilize operating challenges. However, with limited EBIT growth opportunities (outside of significant share gains) and a looming overhang of the potential loss of the Anthem contract, we see limited upside to our fair value assumptions."

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $70.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

UBS, Definitive Agreement

Add Your Comment